Information Provided By:
Fly News Breaks for September 11, 2019
XERS
Sep 11, 2019 | 06:01 EDT
Mizuho analyst Difei Yang lowered her price target for Xeris Pharmaceuticals to $22 from $27 to reflect a downward adjustment of the net price assumption of Gvoke from $260 each to $197 each. The analyst, who believes that Gvoke FDA approval is an "important win" for Xeris, now assumes a lower net price as the company is focused on lowering the patients' out of pocket expenses. She keeps a Buy rating on the shares.
News For XERS From the Last 2 Days
XERS
Mar 27, 2024 | 16:09 EDT
Oppenheimer analyst Leland Gershell initiated coverage of Xeris Biopharma with an Outperform rating and $5 price target. The analyst believes successful commercial execution around the company's portfolio of three specialty drug products will continue to drive seas growth, while "disciplined" spend should enable consistent profitability within 2-3 years. Xeris' XeriJect formulation platform has attracted deals with Amgen and Regeneron, and its broad potential for intravenous-to-subcutaneous lifecycle management with key advantages over Halozymeb could lead to additional industry partnerships over time, the analyst tells investors in a research note. The firm thinks the XP-8121 Phase 2 data, to come mid-year, will increase confidence in the candidate's potential $1B-plus sales opportunity and catalyze investor interest.